Table 4.
Factors associated with severe COVID-19 in patients who had undergone transcatheter aortic valve replacement.
| Univariate Analysis | Multivariate Analysis | |||||
|---|---|---|---|---|---|---|
| OR | 95% CI | p Value | OR | 95% CI | p Value | |
| Age | 0.98 | 0.92–1.05 | 0.649 | |||
| Sex (male) | 0.68 | 0.23–2.07 | 0.502 | |||
| Diabetes | 1.74 | 0.59–5.09 | 0.309 | |||
| Obesity | 0.77 | 0.21–2.78 | 0.688 | |||
| Hypertension | 0.71 | 0.19–2.59 | 0.608 | |||
| Dyslipidemia | 0.85 | 0.29–2.48 | 0.767 | |||
| Atrial fibrillation | 0.57 | 0.18–1.69 | 0.371 | |||
| Peripheral artery disease | 1.07 | 0.33–3.47 | 0.908 | |||
| CKD (Cr > 130 umol/L) | 2.07 | 0.64–6.71 | 0.226 | |||
| Coronary artery disease | 1.63 | 0.56–4.74 | 0.373 | |||
| Heart failure | 0.71 | 0.22–2.29 | 0.566 | |||
| COPD | 1.26 | 0.28–5.75 | 0.761 | |||
| Stroke | 1.03 | 0.23–4.66 | 0.972 | |||
| Prior cancer | 5.08 | 1.68–15.34 | 0.004 | 4.99 | 1.64–15.27 | 0.005 |
| A blood group | 8.38 | 1.86–37.74 | 0.006 | 8.27 | 1.83–37.43 | 0.006 |
| O blood group | 0.19 | 0.04–0.87 | 0.033 | |||
| Aspirin | 0.87 | 0.30–2.52 | 0.804 | |||
| ACE-i/ARB | 1.05 | 0.36–3.01 | 0.934 | |||
| Statins | 0.74 | 0.25–2.15 | 0.579 | |||
Abbreviations: ACE-i, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019.